Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Receivables: 2010-2025

Historic Receivables for Ligand Pharmaceuticals (LGND) over the last 15 years, with Sep 2025 value amounting to $57.6 million.

  • Ligand Pharmaceuticals' Receivables rose 67.73% to $57.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $175.7 million, marking a year-over-year increase of 31.97%. This contributed to the annual value of $38.4 million for FY2024, which is 16.58% up from last year.
  • Ligand Pharmaceuticals' Receivables amounted to $57.6 million in Q3 2025, which was up 39.41% from $41.3 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Receivables high stood at $85.5 million for Q4 2021, and its period low was $28.0 million during Q2 2023.
  • In the last 3 years, Ligand Pharmaceuticals' Receivables had a median value of $36.0 million in 2023 and averaged $36.6 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Receivables soared by 95.51% in 2021, and later tumbled by 64.40% in 2022.
  • Quarterly analysis of 5 years shows Ligand Pharmaceuticals' Receivables stood at $85.5 million in 2021, then plummeted by 64.40% to $30.4 million in 2022, then climbed by 8.19% to $32.9 million in 2023, then increased by 16.58% to $38.4 million in 2024, then spiked by 67.73% to $57.6 million in 2025.
  • Its Receivables stands at $57.6 million for Q3 2025, versus $41.3 million for Q2 2025 and $38.5 million for Q1 2025.